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We presented three cases of inﬂuenza-related severe pneumonia/empyema that occurred in one season.
Case 1: A 76-year-old diabetic man, developed empyema as a result of severe community-acquired
pneumonia (CAP) secondary to Haemophilus inﬂuenzae, as conﬁrmed on sputum culture. Nasal swab
was positive for inﬂuenza A antigen. After drainage of empyema, intravenous peramivir and piperacillin/
tazobactam were administered for 3 days and 2 weeks, respectively, followed by oral levoﬂoxacin for 2
weeks. Eventually, he recovered. In this case, the isolated H. inﬂuenzaewas non-typeable and negative for
beta-lactamase.
Case 2: A 55-year-old man with suspected cerebral infarction and diabetes mellitus (DM) developed
severe pneumonia/empyema as result of hospital-acquired pneumonia (HAP). Although inﬂuenza A
antigen was detected, no bacterium was isolated from the sputum, blood, or pleural effusion. He showed
severe hypoxia, but recovered after administration of peramivir and levoﬂoxacin with prednisolone for 5
days and 2 weeks, respectively.
Case 3: A 76-year-old womanwith heart failure and DM was followed-up on an outpatient basis and was
under nursing home care for four months. Subsequently, she developed pneumonia and was admitted to
our hospital; inﬂuenza antigen was isolated from nasal swab. Healthcare-associated pneumonia (HCAP)/
empyema were diagnosed and were effectively treated with peramivir and levoﬂoxacin for 4 days and 1
week, respectively.
In diabetic patients, inﬂuenza virus may possibly accelerate pneumonia/empyema due to bacterial co-
infection. Although non-typeable H. inﬂuenzae is a rare causative pathogen of empyema, it can be ex-
pected as a result of “pathogen shift” due to the increased use of the H. inﬂuenzae type b vaccine in Japan.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Inﬂuenza virus infection is a major respiratory infectious disease
that generally induces bronchitis [1,2]. It causes an acute febrile
illness with malaise and respiratory failure and is sometimes lethal
in the elderly if the bronchitis develops into pneumonia [3e5].
Inﬂuenza pneumonia has been classiﬁed into primary inﬂuenza
virus pneumonia and bacterial infection-related pneumonia. The
latter type is more frequent and the symptoms, including cough
and sputum production, are similar to those of bacterial pneu-
monia; in addition, inﬁltrative shadows usually appear on chesteases and Infection Control,
ospital, 1-12-1 Fukumuro,
eki).
Ltd. This is an open access article uradiographs [2,5,6]. Synergic effects between inﬂuenza virus and
bacteria have been suggested. However, empyema that is related
with inﬂuenza virus infection is rare [2,7e9], Here, we describe
three patients who were suspected to have developed pneumonia
in association with inﬂuenza virus infection during the 2015e2016
season. These were severe cases of community-acquired pneu-
monia (CAP)/empyema co-infected with Haemophilus inﬂuenzae,
hospital-acquired pneumonia (HAP)/empyema, and healthcare-
associated pneumonia (HCAP)/empyema.
2. Case report
2.1. Case 1
A 76-year-old man presented at the emergency room in
February 2016 with acute pain around the left shoulder and highnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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week. He had a medical history of hypertension and diabetes
mellitus (DM), but had never smoked. Physical examination indi-
cated the following: temperature of 39.5 C, blood pressure of 97/
50 mmHg, respiratory rate of 23 breaths/min, and consciousness
level of E3V4M1 on the Glasgow Coma Scale. There were crackles
(rhonchi) on the lower left lung ﬁeld and chest radiography indi-
cated inﬁltrative shadows and pleural effusion on the left (Fig. 1A
and B). His initial white blood cell (WBC) count was 28,600/L and C-
reactive protein (CRP) was 25.0 mg/dL A 6 French pigtail tube was
inserted subcutaneously under ultrasound guidance. Turbid yellow
ﬂuid was drained and results of the analysis are as follows: pH 7.4,
Total protein 5.2 g/L, Lactate dehydrogenase 4491 U/L, Glucose
66 mmol/L, Cytology neutrophils dominant, and gram negative
bacilli were found. H. inﬂuenzae was identiﬁed in respiratory
specimens and was found as a non-typeable and beta-lactamase
negative type; minimum inhibitory concentration (MIC) test ac-
cording to the Clinical and Laboratory Standards Institute criteria
revealed susceptibility to levoﬂoxacin, piperacillin, ciproﬂoxacin,Fig. 1. Chest radiography and computed tomography images of Case 1 (A and B), Case 2 (C an
suggested severe pneumonia/empyema.and gentamicin, but not to ampicillin (ABPC) and ampicillin/sul-
bactam (ABPC/SBT). Rapid antigen test for inﬂuenza Awas positive.
Thus, we diagnosed that he was inﬂuenza virus-related secondary
bacterial empyema due to H. inﬂuenzae.
After drainage of pleural effusion, intravenous peramivir 300mg
daily for 3 days and piperacillin/tazobactam 4.5 g every 8 hours for
14 days improved the chest radiograph ﬁndings and the inﬂam-
matory markers, such as WBC (7600/L) and CRP (4.46 mg/dL). He
was discharged from the hospital after completing the course of
treatment and continued oral levoﬂoxacin administration for more
two weeks.
2.2. Case 2
A 55-year-old man with a history of DM and suspected cerebral
infarction developed pneumonia 1 month after admission for loss
of consciousness in February 2016. Physical examination revealed
temperature of 38.1 C, blood pressure of 89/60 mmHg, respiratory
rate of 30 breaths/min, dehydration, and crackles (rhonchi) on bothd D), and Case 3 (E and F). All images showed inﬁltration shadows and pleural effusions,
Table 1
Comparison of the three types of inﬂuenza-related empyema.
Patient 1 Patient 2 Patient 3
Category CAP HAP HCAP
Age/Sex 76/Male 55/Male 76/Female
Comorbidity Hypertension Cerebral infarction Heart failure
Diabetes Yes Yes Yes
(HbA1c) (8.4) (6.6) (7.4)
Severity
CURB65 Severe Severe Severe
Chest X-ray Middle range Middle range >2/3
Shock No Yes No
Respirator No Yes No
WBC (cells/L) 28,600 9400 5700
CRP (mg/dL) 25.0 11.1 2.13
Inﬂuenza type A A A
Bacteria H inﬂuenzaea None None
30-day Survival Survived Survived Survived
a Nontyeable ane Beta-lactamase non-producing type, CAP: Community-acquired
pneumonia, HAP; Hospital-acquired pneumonia, and HCAP: healthcare-associated
pneumonia, respectively.
M. Seki et al. / Respiratory Medicine Case Reports 19 (2016) 1e4 3lung ﬁelds. Chest radiography indicated inﬁltrative shadows on
both lung ﬁelds with right-sided pleural effusion (Fig. 1C and D).
Oxygen saturation was 88% at an O2 support of 15 L/min by face
mask. His initial WBC count was 9400/L and CRP was 11.4 mg/dL.
We unfortunately could not perform pleural puncture because his
respiratory status was poor. No bacteriumwas determined in blood
cultures and respiratory specimens, but inﬂuenza A antigen from
nasal swab was positive. He was diagnosed as inﬂuenza-related
HAP/empyema.
The patient was placed on non-invasive positive pressure
ventilation and oxygenation was improved. Intravenous peramivir
300 mg once daily for 5 days, followed by levoﬂoxacin 500 mg once
daily with prednisolone 125 mg once daily for 14 days improved
the chest radiograph ﬁndings and the pneumonia.
2.3. Case 3
A 76-year-old woman with heart failure and DM was admitted
to the emergency room in February 2016 due to dyspnea and
disturbed consciousness. She was followed-up as an outpatient and
had been under nursing care in a geriatric facility for four months.
Physical examination indicated a temperature of 38.5 C, respira-
tory rate of 22 breaths/min, and blood pressure of 108/66 mmHg.
There were crackles (rhonchi) on the left lung ﬁeld and oxygen
saturation was 92% at an O2 support of 10 L/min by mask. Chest
radiography indicated pleural effusion with inﬁltrative shadows
mainly on the left lower lung ﬁeld (Fig. 1E and F). Her initial WBC
count was 5700/L and CRP was 2.13 mg/dL. We could not perform
pleural puncture, and no bacterium was detected in blood cultures
and pleural ﬂuid specimens. However, inﬂuenza A antigen from
nasal swab was positive. Thus, we suspected that she was also
inﬂuenza virus-related secondary bacterial pneumonia.
Intravenous peramivir 300 mg once daily for 4 days and levo-
ﬂoxacin 500 mg once daily for 1 week were administered. She
eventually recovered and returned to the nursing home one month
later after admission.
3. Discussion
Despite major efforts in prevention and treatment, inﬂuenza A
virus infection accounts for signiﬁcant morbidity and mortality
[4,5], which have been attributed to the development of respiratory
complications, including pneumonia.
In this report, we described and compared three inﬂuenza-
related severe pneumonia/empyema cases (Table 1). These cases
were found in one season and hospitalized same period although
each case occur sporadically. Inﬂuenza is usually spread in the
community. However, hospital-acquired and healthcare-associated
inﬂuenza-related complications have recently increased and have
become problems in Japan due to the rising population of the aging
society [10]. Similar cases of HAP and HCAP might be common in
our country recently, but these types were frequently severe
because they usually showed hypoxia that needed O2 support due
to old age and other comorbidities, including heart failure [10,11].
In contrast to HAP and HCAP, CAP is thought to be more com-
mon; for inﬂuenza-related cases, H. inﬂuenzae and Streptococcus
pneumoniae were the major pathogens indicated [1,12]. H. inﬂuen-
zae, especially the non-typeable strains due to the presence of
different or undetectable capsular polysaccharides, has been
known as a causative pathogen of mild mucosal infections, such as
bronchopneumonia or otitis media in elderly persons and children
[13]. However, as demonstrated in our cases, H. inﬂuenzae can also
be a cause of inﬂuenza virus-related severe pneumonia/empyema.
Previously, we reported a case of invasive fatal pneumonia with
sepsis due to a non-typeable H. inﬂuenzae strain and suggested anincreasing incidence of invasive and severe infections, including
pneumonia, bacteremia, and meningitis due to H. inﬂuenzae type b
(Hib) [14]. The incidence of Hib has decreased markedly, probably
due to the widespread use of Hib conjugate vaccines in Japan and
other countries. However, the incidence of invasive infections
caused by non-typeable H. inﬂuenzae has increased [15,16]. This
phenomenon has recently become known as “pathogen shift”, as
exempliﬁed by one of our cases.
In our Case 1, the isolated non-typeable strain was beta-
lactamase negative and ABPC-resistant H. inﬂuenzae (BLNAR). This
type has also increased and reached nearly 50% of all H. inﬂuenzae
strains isolated in Japan [17]. Carbapenems and ﬂuoroquinolones
were known as the effective antibiotics for BLNAR. However, we
underscore rational use of these antibiotics to prevent emergence
of resistant strains of H. inﬂuenzae and other bacteria, including
Pseudomonas aeruginosa [18]. For these reasons, piperacillin may be
an appropriate ﬁrst choice to treat CAP during inﬂuenza season
[19].
All three patients reported here had relatively poor control of
DM (Table 1). An inhibited and weak immune response predisposes
DM as one of the most important comorbidities in pneumonia and
empyema [1,11,20]. Anaerobes, which are difﬁcult to culture, are
known as the causative pathogens in empyema and have been
frequently isolated from DM patients [21]. Unfortunately, the
causative bacteria were not detected in Case 2 and Case 3; never-
theless, anaerobic bacterial etiology was suspected to have wors-
ened the inﬂuenza-related HAP and HCAP in these diabetic
patients.
In conclusion, we encountered three severe inﬂuenza-related
pneumonia/empyema cases in one season and hospitalized same
period although they occurred sporadically. All patients had poorly-
controlled DM and were suggested to have weak immune status.
Although inﬂuenza-related CAPmay be common, inﬂuenza-related
HAP and HCAP may be emerging important diseases in Japan. Due
to the widespread availability of the Hib vaccine, it is important to
be aware that non-typeable H. inﬂuenzae could be a possible
pathogen in inﬂuenza-related severe pneumonia/empyema in
elderly persons.Conﬂict of interest
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